|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
US8651113B2
(en)
*
|
2003-06-18 |
2014-02-18 |
Swr&D Inc. |
Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
|
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
|
ES2537633T3
(es)
|
2004-03-02 |
2015-06-10 |
The Johns Hopkins University |
Mutaciones del gen de PIK3CA en cánceres humanos
|
|
LT2612862T
(lt)
|
2004-05-13 |
2017-01-25 |
Icos Corporation |
Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
|
|
WO2005117889A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic
|
|
US20080287469A1
(en)
*
|
2005-02-17 |
2008-11-20 |
Diacovo Thomas G |
Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
|
|
EP1940386A4
(en)
*
|
2005-09-01 |
2010-06-23 |
Beth Israel Hospital |
WORDMAN'S CONJUGATES AND USES THEREOF
|
|
US20080139457A1
(en)
*
|
2005-09-16 |
2008-06-12 |
Virginia Commonwealth University |
Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
|
|
NZ569086A
(en)
*
|
2005-12-01 |
2011-07-29 |
Trinity College Dublin |
Compositions comprising a Toll-like receptor (TLR) agonist and an immune modulator for treating Th1-mediated conditions, such as cancer and infectious diseases
|
|
ES2436109T3
(es)
*
|
2006-02-09 |
2013-12-27 |
Belrose Pharma Inc. |
Conjugados poliméricos de múltiples brazos de 7-etil-10-hidroxicamptotecina para el tratamiento del cáncer de mama, del cáncer colorrectal, del cáncer de páncreas, de ovario y de pulmón
|
|
US8329683B2
(en)
*
|
2006-06-02 |
2012-12-11 |
Nexgenix Pharmaceuticals, Llc |
Treatment of neurofibromatosis with radicicol and its derivatives
|
|
WO2007143629A1
(en)
*
|
2006-06-02 |
2007-12-13 |
Nexgenix Pharmaceuticals |
Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
|
|
PE20090717A1
(es)
*
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8557807B2
(en)
*
|
2008-01-24 |
2013-10-15 |
Signal Rx Pharmaceuticals, Inc. |
Thienopyranones as kinase inhibitors
|
|
WO2009108704A1
(en)
*
|
2008-02-25 |
2009-09-03 |
Semafore Pharmaceuticals, Inc. |
O-alkylated pi-3 kinase inhibitor prodrug combination
|
|
DE102008001855A1
(de)
*
|
2008-05-19 |
2009-11-26 |
Evonik Degussa Gmbh |
Zweikomponenten-Zusammensetzung zur Herstellung von flexiblen Polyurethan-Gelcoats
|
|
WO2009141823A2
(en)
|
2008-05-22 |
2009-11-26 |
Ramot At Tel Aviv University Ltd. |
Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
|
|
US8524691B2
(en)
|
2008-08-13 |
2013-09-03 |
The Medicines Company |
Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
KR20170060179A
(ko)
|
2008-11-13 |
2017-05-31 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
|
CA2793263C
(en)
|
2009-03-17 |
2015-12-15 |
Woodway Usa, Inc. |
Power generating manually operated treadmill
|
|
AU2010229968A1
(en)
|
2009-03-24 |
2011-10-13 |
Gilead Calistoga Llc |
Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
|
JP2012524126A
(ja)
|
2009-04-20 |
2012-10-11 |
ギリアド カリストガ リミテッド ライアビリティ カンパニー |
固形腫瘍の治療方法
|
|
JP5732453B2
(ja)
|
2009-06-25 |
2015-06-10 |
アルカーメス ファーマ アイルランド リミテッド |
Ｎｈ酸性化合物のプロドラッグ
|
|
PT2445502T
(pt)
|
2009-06-25 |
2017-09-22 |
Alkermes Pharma Ireland Ltd |
Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
|
|
CA2768843A1
(en)
|
2009-07-21 |
2011-01-27 |
Gilead Calistoga Llc |
Treatment of liver disorders with pi3k inhibitors
|
|
US8314934B2
(en)
|
2009-09-01 |
2012-11-20 |
Alltech Associates, Inc. |
Methods and apparatus for analyzing samples and collecting sample fractions
|
|
LT2496567T
(lt)
*
|
2009-11-05 |
2017-11-27 |
Rhizen Pharmaceuticals S.A. |
Nauji benzopirano kinazės moduliatoriai
|
|
NZ604423A
(en)
|
2010-06-24 |
2015-01-30 |
Alkermes Pharma Ireland Ltd |
Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
|
|
KR101591153B1
(ko)
|
2010-12-20 |
2016-02-02 |
그렌마크 파머수티칼스 에스. 아. |
Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
|
|
ES2972387T3
(es)
|
2011-03-18 |
2024-06-12 |
Alkermes Pharma Ireland Ltd |
Composiciones farmacéuticas que comprenden ésteres de sorbitán
|
|
US9359376B2
(en)
*
|
2011-04-08 |
2016-06-07 |
Sphaera Pharma Pte. Ltd |
Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
|
|
KR20140067070A
(ko)
*
|
2011-08-31 |
2014-06-03 |
말린크로트 엘엘씨 |
Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질
|
|
WO2013088255A1
(en)
|
2011-12-15 |
2013-06-20 |
Alkermes Pharma Ireland Limited |
Prodrugs of secondary amine compounds
|
|
BRPI1107182B1
(pt)
*
|
2011-12-29 |
2022-03-08 |
Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig |
Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
|
|
ES2848273T3
(es)
|
2012-03-05 |
2021-08-06 |
Gilead Calistoga Llc |
Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
|
|
IN2014MN01819A
(enExample)
|
2012-03-05 |
2015-07-03 |
Univ Ramot |
|
|
WO2013142202A1
(en)
|
2012-03-19 |
2013-09-26 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising glycerol esters
|
|
CA2867121C
(en)
|
2012-03-19 |
2021-05-25 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising fatty acid esters
|
|
US9999670B2
(en)
|
2012-03-19 |
2018-06-19 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising benzyl alcohol
|
|
JP6654042B2
(ja)
|
2012-09-19 |
2020-02-26 |
アルカームス ファーマ アイルランド リミテッド |
貯蔵安定性が改善された医薬組成物
|
|
WO2014068070A1
(en)
|
2012-10-31 |
2014-05-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
|
HK1214533A1
(zh)
|
2013-03-15 |
2016-07-29 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
EP2986294A4
(en)
|
2013-04-17 |
2016-11-16 |
Biopharma Works |
PROCESS FOR PAIN TREATMENT
|
|
EP2986295A4
(en)
*
|
2013-04-17 |
2016-11-09 |
Biopharma Works |
PROCESS FOR PAIN TREATMENT
|
|
JP2017500319A
(ja)
|
2013-12-20 |
2017-01-05 |
ギリアード カリストガ エルエルシー |
（ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
|
|
EP3083630B1
(en)
|
2013-12-20 |
2019-08-21 |
Gilead Calistoga LLC |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
US11066649B2
(en)
|
2014-03-19 |
2021-07-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for inducing human cholangiocyte differentiation
|
|
AU2015231278B2
(en)
|
2014-03-20 |
2020-01-23 |
Alkermes Pharma Ireland Limited |
Aripiprazole formulations having increased injection speeds
|
|
US11021467B2
(en)
|
2014-06-13 |
2021-06-01 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
WO2016065142A2
(en)
*
|
2014-10-22 |
2016-04-28 |
The Johns Hopkins University |
New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
|
|
NZ731185A
(en)
|
2014-10-29 |
2024-03-22 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for mt1-mmp
|
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
DK3319643T3
(da)
*
|
2015-07-07 |
2020-06-15 |
Five Eleven Pharma Inc |
HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CN118063537A
(zh)
|
2015-09-08 |
2024-05-24 |
莫纳什大学 |
定向淋巴的前药
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
US10709926B2
(en)
|
2015-10-06 |
2020-07-14 |
Woodway Usa, Inc. |
Treadmill
|
|
MX389001B
(es)
|
2015-10-23 |
2025-03-20 |
Navitor Pharm Inc |
Moduladores de interacción de sestrina-gator2 y sus usos.
|
|
CN108350018A
(zh)
*
|
2015-11-17 |
2018-07-31 |
日产化学工业株式会社 |
寡核苷酸的制造方法
|
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
|
WO2017162536A1
(en)
|
2016-03-21 |
2017-09-28 |
H. Lundbeck A/S |
Vortioxetine prodrugs
|
|
WO2017175022A1
(en)
|
2016-04-07 |
2017-10-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for inhibiting mast cell degranulation
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
EP3808748B1
(en)
|
2016-06-21 |
2026-05-20 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
EP3906979B1
(en)
|
2016-07-01 |
2026-07-22 |
Woodway USA, Inc. |
Motorized treadmill with motor braking mechanism and methods of operating same
|
|
US10072032B2
(en)
*
|
2016-09-19 |
2018-09-11 |
Afton Chemical Corporation |
AminoBisPhosphonate antiwear additives
|
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
CN110300590A
(zh)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
EP3559018A1
(en)
|
2016-12-23 |
2019-10-30 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
ES2985986T3
(es)
|
2017-01-06 |
2024-11-08 |
Bicyclerd Ltd |
Conjugado biciclo para tratar el cáncer
|
|
WO2018140730A1
(en)
|
2017-01-27 |
2018-08-02 |
Signalrx Pharmaceuticals, Inc. |
Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
|
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
WO2018199174A1
(ja)
*
|
2017-04-25 |
2018-11-01 |
生化学工業株式会社 |
第３級アミン化合物又はイミン化合物－ポリマーコンジュゲートとその製造方法
|
|
ES3040534T3
(en)
|
2017-04-26 |
2025-11-03 |
Navitor Pharm Inc |
Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
|
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN119285538A
(zh)
|
2017-05-04 |
2025-01-10 |
发现号收购集团 |
作为例如用于保护植物的害虫防治剂的2-{[2-(苯氧基甲基)吡啶-5-基]氧基}乙胺衍生物及相关化合物
|
|
CN108929329B
(zh)
*
|
2017-05-24 |
2020-12-11 |
中国医学科学院药物研究所 |
2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
|
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
|
IL317854A
(en)
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
EP4306524A3
(en)
|
2017-08-29 |
2024-09-11 |
PureTech LYT, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
CN108003188A
(zh)
*
|
2017-12-25 |
2018-05-08 |
长春吉大天元化学技术股份有限公司 |
一种烷基磷酸酯类化合物的新型纯化方法
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
KR20260028873A
(ko)
|
2018-02-27 |
2026-03-04 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
|
AU2019230014B2
(en)
|
2018-03-05 |
2024-11-28 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
|
EP3784669B1
(en)
|
2018-04-24 |
2023-10-25 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
IL301501B2
(en)
|
2018-04-24 |
2024-10-01 |
Vertex Pharma |
Antiproliferation compounds and uses thereof
|
|
US10980784B2
(en)
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12570668B2
(en)
|
2018-07-23 |
2026-03-10 |
Signalrx Pharmaceuticals, Inc. |
Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
JPWO2020050378A1
(ja)
*
|
2018-09-06 |
2021-08-30 |
生化学工業株式会社 |
第３級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
WO2020086816A1
(en)
|
2018-10-24 |
2020-04-30 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
USD930089S1
(en)
|
2019-03-12 |
2021-09-07 |
Woodway Usa, Inc. |
Treadmill
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CA3150492A1
(en)
|
2019-09-11 |
2021-03-18 |
Donna L. Romero |
Usp30 inhibitors and uses thereof
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
AU2020376950B2
(en)
|
2019-11-01 |
2026-06-11 |
Supernus Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
JP7810970B2
(ja)
|
2020-02-05 |
2026-02-04 |
シーポート・セラピューティクス・インコーポレイテッド |
神経ステロイドの脂質プロドラッグ
|
|
AR121506A1
(es)
|
2020-03-03 |
2022-06-08 |
Pic Therapeutics Inc |
Inhibidores del eif4e y sus usos
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN116348476A
(zh)
|
2020-08-03 |
2023-06-27 |
拜斯科技术开发有限公司 |
基于肽的接头
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
US20250059164A1
(en)
|
2023-06-23 |
2025-02-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4780462A1
(en)
|
2023-09-21 |
2026-07-29 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|